Clinical Trials

Clinical trials play a crucial role in advancing the science of medicine through human trials. Patients participating in clinical trials often have access to the very latest medications and protocols that may not otherwise be available. Clinical trial participants are actively contributing to the advancement of science as their participation helps perfect future treatment options for transplant patients. 

These are the current clinical trials conducted by the UM Division of Transplantation:

FDA approved for additional uses

Research Study of ATG and Rituximab in Renal Transplantation (RESTARRT) (ongoing, not recruiting)
Immunosuppression With Antithymocyte Globulin, Rituximab, Tacrolimus, Mycophenilate Mofetil and Sirolimus, Followed by Withdrawal of Immunosuppression, in Living-donor Renal Transplant Recipients

Belatacept in Renal Transplantation with Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores (currently recruiting)
A 12 Month, Single-center, Non-randomized, Open-label Study of Outcomes of Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores in de Novo Renal Transplant Recipients

Drugs currently in phase 2 or 3 testing

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney (currently recruiting)
A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation (currently recruiting)
A 12-month Randomized, Multiple Dose, Open-label, Study Evaluating Safety, Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy of an Anti-CD40 Monoclonal Antibody, CFZ533, in Combination With Mycophenolate Mofetil (MMF) and Corticosteroids (CS), With and Without Tacrolimus (Tac), in de Novo Renal Transplant Recipients

Studies to devise new tests to reduce rejection

Non Invasive Blood Test to Diagnose Acute Rejection AFTER Kidney Transplantation (DART) (currently recruiting)
Circulating Donor-Derived Cell-free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients

Average rating:
         
(based on 0 ratings)